Drug Trial Radar · NCT00562224
Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients
Last checked: Nov 19, 2026Latest source record: Sep 28, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Planned (sponsor's estimate)
Start
Nov 2007
Primary completion
Jun 2010
Study completion Sep 2010
Sponsor
- Lead sponsor
- Pharmacyclics LLC.AbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Nov 21, 2007
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To determine the highest dose of study drug that can be taken without causing serious side effects in patients with advanced cancer. The study will look at safety of the study drug and whether the treatment schedule is tolerated by patients.
Conditions
- Neoplasms by Site
- Lymphoma, Non-hodgkin
- Hodgkin Disease
- Multiple Myeloma
- Leukemia, Lymphocytic, Chronic
Interventions
PCI-24781Drug
Up to 7 cohorts will receive PCI-24781 orally at doses starting at 30 mg/m2 three times a day approximately 4 hours apart ("TID"), up to 90 mg/m2, administered 5 days/week during the first 21 days of each 28 day cycle until MTD is reached. If a dose limiting toxicity (DLT) occurs, then the next cohort will receive PCI-24781 twice a day approximately 4 hours apart ("BID"). If a DLT occurs on the "BID" schedule, the subsequent cohort will receive PCI-24781 BID for 7 days every other week (2 times in a 28 day cycle). If a DLT occurs on this dosing schedule, then the next cohort will receive PCI-24781 BID for 5 days/week every other week (2 times in a 28 day cycle) until the maximum tolerated dose is reached.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limiting toxicity assessment at the end of the first 28 day cycle.Time frame: at the end of the first 28 day cycle
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
California Cancer Care
Greenbrae, California
University of Chicago
Chicago, Illinois
Sarah Cannon Research Institue
Nashville, Tennessee
MD Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.